Benzinga's Top Upgrades
Analysts at Morgan Stanley upgraded Bristol-Myers Squibb Company (NYSE: BMY) from “equal-weight” to “overweight.” The target price for Bristol-Myers Squibb has been raised from $45 to $60. Bristol-Myers Squibb's shares closed at $48.77 on Friday.
Analysts at Goldman Sachs upgraded Generac Holdings (NYSE: GNRC) from “sell” to “neutral.” The target price for Generac Holdings has been raised from $32 to $49. Generac's shares closed at $50.44 on Friday.
Guggenheim Securities upgraded FMC Technologies (NYSE: FTI) from “neutral” to “buy.” The target price for FMC Technologies is set to $60. FMC Technologies' shares closed at $51.13 on Friday.
Analysts at Bank of America upgraded Astrazeneca PLC (NYSE: AZN) from “underperform” to “neutral.” Astrazeneca's shares closed at $52.74 on Friday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.